Deseret Mutual Benefit Administrators Has $640,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Deseret Mutual Benefit Administrators decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 609 shares of the biopharmaceutical company’s stock after selling 13 shares during the period. Deseret Mutual Benefit Administrators’ holdings in Regeneron Pharmaceuticals were worth $640,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in REGN. Norden Group LLC raised its position in Regeneron Pharmaceuticals by 48.1% during the first quarter. Norden Group LLC now owns 388 shares of the biopharmaceutical company’s stock worth $373,000 after acquiring an additional 126 shares in the last quarter. Quent Capital LLC raised its position in Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 19 shares in the last quarter. Csenge Advisory Group raised its position in Regeneron Pharmaceuticals by 12.3% during the first quarter. Csenge Advisory Group now owns 449 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 49 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Regeneron Pharmaceuticals by 33.7% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 1,588 shares of the biopharmaceutical company’s stock worth $1,528,000 after acquiring an additional 400 shares in the last quarter. Finally, AIA Group Ltd raised its position in Regeneron Pharmaceuticals by 45.9% during the first quarter. AIA Group Ltd now owns 6,888 shares of the biopharmaceutical company’s stock worth $6,630,000 after acquiring an additional 2,166 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.48% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Royal Bank of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,092.62.

Regeneron Pharmaceuticals Price Performance

REGN opened at $816.65 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $90.03 billion, a price-to-earnings ratio of 20.21, a P/E/G ratio of 3.17 and a beta of 0.15. The firm’s fifty day moving average price is $1,035.92 and its two-hundred day moving average price is $1,038.36. Regeneron Pharmaceuticals, Inc. has a 1 year low of $783.57 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.